Adult stem cells have therapeutic potential because of their intrinsic capacity for self-renewal, especially for bone regeneration. The present study shows the utility of ex vivo modified mesenchymal stem cells (MSC) to enhance bone density in an immunocompetent mouse model of osteopenia. MSC were transduced ex vivo with a recombinant adeno-associated virus 2 (rAAV2) expressing bone morphogenetic protein 2 (BMP2) under the transcriptional control of collagen type-1a promoter. To enrich bone homing in vivo, we further modified the cells to transiently express the mouse a4 integrin. The modified MSC were systemically administered to ovariectomized, female C57BL/6 mice. Effects of the therapy were determined by dual-energy X-ray absorptiometry, 3D micro-CT, histology and immunohistochemistry for up to 6 months.
Introduction
Advancement in cell and gene therapy approaches to provide long-term phenotypic correction may become a clinical possibility by genetic modifications of stem cells in vitro before transplantation. [1] [2] [3] Adult mesenchymal stem cells (MSC) represent an ideal source for ex vivo therapy for the treatment of genetic, age-related and segmental bone defects to increase bone mass. 4 Recent studies have shown that pluripotent MSC can home to the bone marrow and participate in new bone formation, raising the possibility that MSC-based therapies may be developed for effective intervention of bone loss. [5] [6] [7] One of the approaches to use MSC for osteoinductive therapy is genetic modification of the cells ex vivo to function as continuous source for providing progeny osteoblasts. Induction of endogenous cytokine and growth factor production by exogenous stimuli from implanted MSC may further mobilize progenitor cells and improve tissue repair. 8 MSC, cultured ex vivo with appropriate growth factors under controlled conditions, can retain multilineage potential and can differentiate into adipocytes, osteocytes, chondrocytes or myocytes. MSC can be used to perform a variety of functions in tissue repair models, as tissue-protective cells in brain injury such as acute cerebral infarction 9 and as drug delivery vehicle for tumor-stromal cells, targeting invasive and metastatic malignant tumor cells. 10, 11 MSC migration to the sites of injury and their differentiation to replace existing damaged tissues are not clearly defined processes and key effectors that control these restricted processes are being elucidated. Despite the potential of delivered MSC in vivo, site-specific differentiation and integration of the injected cells into existing tissues are still being optimized. Nonetheless, potential mobilization of progenitors from the bone marrow is associated with exogenous stimuli secreted by the MSC to stimulate endogenous progenitors. 12 Recombinant viruses are efficient for gene transfer into many cell types including MSC. Among the vectors currently being tested, adeno-associated virus (AAV) is a nonpathogenic, replication-defective vector capable of providing long-term gene expression with very low vector immunity. We recently demonstrated efficient transduction of MSC by rAAV2 and expression of transgenes during multistage osteogenic differentiation. 13, 14 In this study, we describe the potential of MSC, transduced ex vivo by an rAAV2 encoding bone morphogenetic protein 2 (BMP2) in long-term correction of osteopenia in a mouse model of osteoporosis. BMP signaling regulates body axis determination, morphogenesis in limb bud, apoptosis in finger development and differentiation of cells in both ectodermal and mesenchymal origin. [15] [16] [17] [18] However, the molecules involved in BMP regulation of biological events have not been fully understood. Molecular analyses of the mechanisms of biological events induced by the BMP2 have identified key regulatory transcription factors to be the target. [19] [20] [21] Bone cell development is also regulated by BMPs, which induces osteogenesis when implanted in ectopic sited through stimulation of the differentiation of mesenchymal cells into osteoblastic cells. [22] [23] [24] [25] BMP actions are also under the influence of the signals triggered by the interaction between osteoblastic cells and extracellular matrix. 26, 27 Despite the potential of MSC in ex vivo therapy, a major limitation of using genetically modified MSC is bone-specific homing upon autologous transfer. To overcome this, we used a novel strategy to transiently express mouse a4 integrin ectopically on these cells before in vivo transfer. Heterodimerization of the mouse a4 integrin with endogenous b1 integrin was confirmed to mediate enhanced bone homing of the MSC, and induction of new bone formation as determined by several bone parameters. 28 Further, BMP2 expression by transplanted MSC was found to effect therapeutic gain also by mobilization of endogenous progenitors.
Results

Cell phenotyping
The phenotype of MSC isolated and cultured from lowdensity bone marrow cells of C57BL/6 mice was determined by flow cytometry. The cells were negative for CD34 and CD45 surface markers and positive for CD29, CD44, Sca1 and CD106 (Supplementary Figure 1) . Multilineage property of MSC was confirmed by differentiating the cells into adipocytes, chondrocytes, osteoblasts or myocytes as before (Supplementary Figure 2) . 28 
Expression of BMP2 in rAAV2-BMP2-transduced mouse MSC
To demonstrate the expression of BMP2 following rAAV2 transduction, we transduced mouse MSC with rAAV2-BMP2 at n multiplicity of infection (MOI) of 1000. To determine the influence of a4-integrin on the expression of BMP2 in MSC, we transiently transfected cells with the mouse a4-integrin plasmid. Expression of BMP2 protein in MSC was detected by immunoblotting with an anti-mouse BMP2 monoclonal antibody and a goat antimouse immunoglobulin (IgG), conjugated to horseradish peroxidase (HRP). The secreted BMP2 protein by rAAV2-BMP2-transfected MSC was detected in culture media after concentration and immunoblot analysis but not in rAAV2-GFP-infected MSC. The molecular mass of the secreted BMP2 as 21 kDa protein indicated that it is in mature form (Figure 1) . Results, shown in Figure 1 indicate that transient expression of a4 integrin does not affect BMP2 expression in mouse MSC.
By enzyme-linked immunosorbent assay, we determined the amount of BMP2 in rAAV-BMP2-transduced MSC to be 3268±591 pg ml À1 per 10 6 cells in nonosteogenic medium. However, the level of BMP2 increased several fold to 47926±8165 pg ml À1 when the cells were cultured in osteogenic medium.
Transient, ectopic expression of a4b1 integrin enhances bone homing of MSC
To determine the efficacy of MSC expressing a4-integrin in bone homing in vivo, we intravenously injected the cells through tail vein in C57BL/6 mice after transient transfection with the mouse a4-integrin expression plasmid. A total of 2 Â 10 6 MSC were administered per mouse for 5 consecutive days by i.v. injection. All animals survived after the MSC infusion. In situ hybridization was performed in decalcified bone sections of long bones (femur and tibia) with Y-chromosomespecific probe (Supplementary Figure 3 , in situ method). 28 For the quantification of positive signal in the region of interest (ROI), below the growth plate of each femur section, we counted at least five random fields in a microscope (Supplementary Figure 3) . 28 Results indicated enriched homing of MSC to the long bones, as a result of expression of a4 integrin on these MSC similar to our findings in recently published reports. 28 There was no significant difference in the bone homing of MSC between untransduced MSC and rAAV2-BMP2-transduced MSC injection in the transplanted mice (Supplementary Figure 3 ). Semiquantitative real-time PCR analysis for the biodistribution of donor cells in different tissues indicated a significant increase in homing of the transplanted cells to bone marrow when the cells were transfected to express a4 integrin before transplantation. This was also accompanied by reduction in the number of cells homing to other tissues including lung, liver, kidney and lymph node (Supplementary Figure 4) . We were able to amplify Y-specific PCR from total DNA isolated from harvested bone marrow of transplanted animals after 4 months of transplantation (data not shown), which indicates long-term survival of transplanted MSC.
Quantification of BMP2 level in the serum samples of transplanted animals
No significant differences were observed in the circulating BMP2 level in the serum samples collected from were kept on a phytoestrogen-free diet 13 and their baseline dual-energy X-ray absorptiometry (DXA) was obtained before the start of in vivo MSC injection experiment. Ovariectomized female C57BL/6 mice (6-week old) were intravenously injected with rAAV2-BMP2-transduced MSC, rAAV2-GFP-transduced MSC, unmodified MSC and transiently transfected with mouse a4-integrin plasmid. Quantitative analysis of bone mineral density (BMD) data by analysis of variance (ANOVA) indicated a significant difference between the group of animals transplanted with MSC-rAAVBMP2+a4-integrin-treated group compared to other MSC-transplanted control groups (Po0.001). Noninvasive DXA analysis performed 5 weeks after transplantation revealed a significant increase in total bone mass and trabecular BMD in mice treated with AAV2-BMP2-transduced MSC and transiently transfected with a4-integrin plasmid compared to mice treated with rAAV2-GFP-transduced MSC and transiently transfected with a4-integrin plasmid, rAAV2-BMP2-transduced MSC, MSC transiently transfected with a4-integrin plasmid, unmodified MSC (Po0.001) or naive group (Po0.0001). Increase in the BMD values was found to be statistically significant compared to other control MSCtransplanted groups (Po0.001) and untreated control animals ( Figure 2, Po0.0001 ). An increase of 21.5 ± 2.5% in BMD values, in group of mice injected with MSC transduced with rAAV2-BMP2 and transiently transfected with a4-integrin plasmid was observed at week 5 compared to the other MSC-transplanted controls (all comparisons, Po0.001). This increase in BMD compared to the controls was maintained until 15 weeks (Figure 2 ). Statistical analysis of BMD in the group of animal transplanted with MSC-rAAV-GFP+a4 integrin, MSC+a4 integrin, MSC-rAAV-BMP2 or MSC only had statistically significant increase in BMD compared to untreated control group of animal (Figure 2 , Po0.05). We also tested intramuscular injection of 2 Â 10 11 vg per mouse rAAV-Col.I:BMP2 virus and monitored the BMD for 10 weeks but did not observe significant bone growth in the animals ( Figure 2) . Figure 2 data suggest that increase in BMD reached a plateau after week 5 and did not increase during weeks 10 and 15. To explain this observation, we looked into the osteoblasts/osteoclasts ratio in the bone sections from different treatment groups and determined no significant differences (P40.05), indicating that a coupled bone formation and remodeling process was maintained after the initial increase in bone formation activity.
Micro-CT analysis of bone microarchitecture. Cohorts of MSC-transplanted mice were killed at regular time points and their femur bones were analyzed by micro-CT. Results of this analysis, shown in Figure 3a , indicated that increase in total BMD in femora of BMP2-expressing MSC-treated mice was accompanied by a corresponding decrease in endosteal circumference. Meanwhile, there was no effect on periosteal circumference (data not shown), suggesting that MSC expressing BMP2 exerted the increased bone formation on the endosteal bone surface. Several microarchitectural parameters were collected from the micro-CT analysis. Results of these analyses, shown in Figure 3b , indicated that the group of mice transplanted with rAAV2-BMP2-transduced MSC had significant bone growth compared to the controls. The observed increase was seen in both bone mass (bone volume) and bone activity (as reflected by the parameters for bone surface and bone surface/volume ratio). Significant increase in bone structural parameters of trabecular bones, bone volume by tissue volume (BV/ TV), ratio of bone surface to bone volume (BS/BV), trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular connectivity density (ConnD) and degree on BMP2 was quantified using BMP2 Quantikine kit (R&D Systems). A standard curve was generated using purified rhBMP2 protein. 6 MSC that were either unmodified, transduced with rAAV2-col-BMP2 or rAAV2-GFP for 5 consecutive days of intravenous injection. Before implantation, the cells were transfected with an expression plasmid encoding mouse a4 integrin. Total BMD was determined by noninvasive dual-energy X-ray absorptiometry (DXA) at the start of the experiment and thereafter at 5-week intervals. Mice were anesthetized with isoflurane during DXA analysis. DXA was carried out in a GE-Lunar PIXImus and data analyses were carried out with PIXImus software version 1.43.020. *Po0.001 compared to control, AAV2-GFP and MSC-only treatments.
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Histological and immunohistochemical evaluation of bone tissues. Results of bone architecture by DXA and micro-CT were further supported by histological analysis. At 5, 10 and 15 weeks after the MSC transplantation, mice from each group were killed and bone tissues were examined by histology. Standard trichrome staining confirmed an increase in the bone mass in mice treated with rAAV2-BMP2-transduced MSC. Trabecular bone ). Similar to our earlier observation, expression of a4-integrin on MSC leads to several fold increase in bone-specific homing although, we were able to detect presence of transplanted cells in other tissues like lung, liver, pancreas, kidney and fat tissues, comparatively in lower amounts. 28 Cell proliferation assay of MSC isolated from transplanted animals. Mesenchymal stem cells isolated from bone marrow of animals transplanted with rAAV-BMP2 and transfected with a4-integrin plasmid did show comparatively higher proliferation capabilities in an in vitro cell proliferation assay compared to all other control groups (Po0.05; Figure 5a ). MSC included for these studies were GFP negative and represented only endogenous MSC. In vitro proliferation was higher in bone marrow stroma harvested from rAAV-BMP2-treated mice at days 2, 4, 6 and 8 of culture (Figure 5a ). These data are consistent with the observed increase in the Histological evaluation of bone sections to determine number of osteoblasts in the bone active area. Bone histology and histomorphometry following the rAAV-BMP2 therapy showed more cuboid-shaped osteoblasts lining the mineralized trabecular bones. Counting of the number of osteoblasts in five separate fields indicated a significant increase in the number of osteoblast in the MSC-rAAV-BMP2 group compared to the naive or MSCtransplanted group (Figure 5c ). Taken together, these data showing more proliferative capabilities of harvested bone marrow stroma, having higher osteocompetent pool of cells with increased number of osteoblasts in the bone sections, indicate involvement of the pro-osteoblastic process inside bone in the presence of MSC expressing BMP2 in the bone marrow microenvironment.
Immunohistochemistry in bone sections from OVX mice transplanted with BMP-transduced MSC from GFP transgenic mice indicated more Runx2-positive cells around the trabecular area compared to nonspecific control vector-transduced MSC (Figure 6a ). When this region was stained with GFP antibody, there were no significant numbers of positive cells in the new boneforming area, which showed positive staining for Runx2. By including bone sections from control GFP transgenic mouse, we confirmed that the lack of GFP staining is not because of the inability of antibody to detect GFP in Runx2-positive cells in this region. Quantification of the Runx2-positive cells in the bone sections from each of the experimental groups indicated that AAV-BMP2-transduced, and transplanted MSC have significant contribution in new bone growth by enriching endogenous progenitors, mediated by BMP2 expression from the transplanted MSC (Figure 6b ). Three-point bending analysis as a functional testing for the quality of bones showed a significant increase in peak load, stiffness and toughness of femur and tibia of BMP2 therapy group compared to other controls (data not shown).
Discussion
The plasticity of MSC for multilineage differentiation has opened new prospects for clinical applications. 29, 30 Transplantation of genetically modified MSC has the potential to correct disorders of bone, cartilage and muscle. [31] [32] [33] A continuous source of osteoblast recruitment for bone growth, remodeling and fracture repair is ensured by mesenchymal progenitor cells, which have been identified in the bone marrow and other tissues. 34, 35 Migration of bone-forming cells is an important event during various physiological and pathological situations and their differentiation to cell lineages is controlled by bioactive factors found in the local microenvironment or secreted by the engineered cells. Thus, in principle, ex vivo therapy to increase bone formation may be accomplished by i.v. injections of MSC expressing therapeutic transgenes. However, engraftment potential of ex vivo modified MSC remained a limiting factor. 36 Use of an ectopic bone homing signal in MSC in the present study was found to significantly increase bone homing of genetically modified MSC. The a4b1 integrin is a heterodimer present in bone homing hematopoietic stem cells and metastatic cancer cells. 37, 38 Because the homing signal is required only during the initial phase of MSC repopulation, it was adequate to transiently express a4 integrin using a plasmid vector.
Because in autologous stem cell therapy using MSC, cells are transduced ex vivo and maintained in culture until optimal transgene expression has occurred, vector structural proteins are greatly diminished and virtually no immune reactions against the vector would be expected. In addition, rAAVs do not encode for vector proteins, the only transgene expressed will be BMP2 or any such therapeutic transgene. In the present study, MSC from GFP transgenic mice served as a means for long-term in vivo cell tracking. We cannot exclude the possibility of downregulation of GFP expression with terminal differentiation in vivo or the possibility of promoter silencing. 39 Based on the results, in vivo osteoblast differentiation by transplanted MSC alone is unlikely to have a significant contribution to the therapeutic benefit observed in this study. MSC have been shown to augment tissue repair primarily through actions of trophic mediators in a variety of injury models. [40] [41] [42] [43] It is therefore likely that transplanted MSC after homing to bone sites induced the expression of growth factors in the local microenvironment, which recruited endogenous progenitors to promote osteogenesis. This is corroborated by both quantitative PCR and immunohistochemistry in the present study. BMP2 expression from AAV-BMP2 using a 2.3 kb collagen type I promoter, specifically expressed in MSC, 44 restricted the transgene expression in the bone marrow microenvironment.
Results of the present study demonstrated that mice injected with MSC expressing BMP2 improve bone growth beginning week 5 as indicated by increased BMD compared with only MSC-injected mice or control ovariectomized mice. There was significant increase in BMD in the group of mice injected with rAAV2-BMP2 transduced and transiently transfected with mouse a4-integrin plasmid compared with the rAAV2-BMP2 group, possibly because a4 expressing MSC homed significantly more in the bone sites exerting better Therapeutic potential of adult stem cells S Kumar et al therapeutic effect. Although the precise mechanism by which this effect occurred remains to be elucidated, increased proliferation capabilities of harvested bone marrow stroma from transplanted animals, presence of immature pre-osteoblast marker Runx2-positive cells in bone marrow stroma and the observed augmentation in osteoblast number combined with increased trabecular bone are suggestive of a pro-osteoblastic mechanism. The robust trabecular bone growth observed in mice injected with MSC expressing BMP2, however, is unlikely to be due to osteoblast differentiation of the transplanted MSC alone as bone growth was sustained even after 15 weeks, when there was very little identification of donor MSC within the bone sections. During early time point, some GFP-positive cells were found in close proximity of bone remodeling area near trabecular bones. 28 Thus, BMP2 production by the transplanted MSC may have induced paracrine effects for pro-osteoblastic local bone growth milieu by influencing the existing endogenous progenitors inside the bone marrow, either by cell recruitment and/or cell proliferation. Experimental data from this study indicate that there was more osteocompetent pool Therapeutic potential of adult stem cells S Kumar et al of cells in the AAV-BMP2 MSC group, which may be derivatives of osteoprogenitor cells as a result of either active proliferation of available progenitors or active recruitment of osteoprogenitors, as they did not stained positive with GFP antibody. Progenitor-cell-based therapy offers certain physiological advantages compared to direct application of viral vectors in vivo by gene therapy, even though improved bone growth has been observed with other modalities. [45] [46] [47] Integration of the transgene into the host chromosome is not required and supraphysiological overexpression of transgene is necessarily avoided. Instead, the transplanted host cellular machinery regulates the production of cellular growth factors in response to the immediate need to the appropriate microenvironment. In addition, application of protein therapy requires multiple administration of products, whereas genetically modified cell-based strategies can theoretically continue to produce a protein of interest until the cell is cleared from the transplanted subject.
Our data support the therapeutic potential of MSC in the restoration of bone growth in an osteopenia model. These effects appear to be also mediated by the creation of a pro-osteoblastic environment in the presence of MSC expressing BMP2 and not only by direct incorporation of transplanted MSC. Indirect mechanisms such as cell recruitment and paracrine effects of growth factors and cytokines produced by MSC are likely to be responsible for the observed bone growth improvement. Thus, the potential of this therapy may also be used in pathological situations requiring short-term benefits, such as multiple fractures and osteolytic bone damage in cancer.
Materials and methods
Cells and reagents
HEK293 was purchased from ATCC and maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum. Restriction endonucleases and other modifying enzymes were purchased from either NEB (Beverly, MA, USA) or Promega (Madison, WI, USA). BMP2 and a4-integrin antibodies were purchased from R&D systems (Minneapolis, MN, USA) and eBiosciences (San Diego, CA, USA), respectively. Recombinant BMP2 was purchased from R&D Systems.
Construction of plasmids and production of recombinant AAV2
All AAV2 plasmids were constructed using pSub201 as the backbone. cDNA encoding rat BMP2 was kindly provided by Dr Chen (University of Texas at San Antonio, TX, USA) and a cDNA encoding mouse a4 integrin was kindly provided by Dr David Rowe (University of Connecticut Health Science Center, Farmington, CT, USA). The coding sequence of rat BMP2 was subcloned under collagen type I promoter and mouse a4 integrin was subcloned under the control of cytomegalovirus (CMV) promoter. 48 Recombinant AAV2 encoding GFP was described earlier. 48 Packaging of rAAV2 was carried out in an adenovirus-free system as described. 48 Purification of the virions was carried out in a discontinuous iodixanol gradient centrifugation followed by heparin affinity chromatography. Particle titers of the purified virions were determined by quantitative slot blot analysis as described. 48 Primary mouse MSC culture, gene transfer and enrichment of a4-integrin-positive cells Ovariectomized C57BL/6 mice were purchased from the National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD, USA), and GFP transgenic mice (C57BL/6-Tg(ACTbEGFP)1Osb/J) were purchased from the Jackson Laboratories (Barr Harbor, ME, USA). All animal protocols were approved by IACUC. To obtain bone marrow stromal cells, we killed 4-to 6-week-old male mice and flushed bone marrow from the femur and tibia, and purified the marrow mononuclear cells by Ficoll gradient. 28 Bone marrow stromal cells were grown in Stemline MSC expansion medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), 10 À9 M FGF2 to maintain the cells in pluripotent and undifferentiated state. 49 Residual macrophages from the MSC culture were removed by IMAC using antimouse CD11b beads (catalog no. 558013 BD IMag; BD Biosciences, San Diego, CA, USA). After 14 days, the adherent stromal cells were split before attaining confluence to avoid possible onset of differentiation. The cells were routinely prepared and used for in vitro and in vivo studies as low passage cultures (passage [4] [5] [6] [7] [8] .
Undifferentiated MSC were transduced with 1000 MOI (1 MOI ¼ 50 genomic particles) of rAAV2-BMP2 or rAAV2-GFP, that is, an MOI of 1000 requires 50,000 viral genomic particles. Virus infection was performed in Opti-MEM for 2 h at 37 1C following which complete medium with FGF2 was added. The cells were grown for 10 more days before transplantation into mice.
Transient, ectopic expression of a4 integrin in cultured MSC
To enrich MSC engraftment to bone, we transiently expressed the a4 integrin by plasmid transfection. 28 A 3.5 kb full-length cDNA fragment of the murine a4 integrin subunit was cloned into pcDNA3.1 under the transcriptional control of CMV promoter for transient transfection. Plasmid (10 mg) was used for transient transfection in 175 mm culture flask using FuGENE 6 (Roche Diagnostics, Indianapolis, IN, USA) transfection reagent following the manufacturer's instructions. Transfection efficiency was found to be between 70 and 80%. Ectopic expression of a4 was confirmed by staining the cells using PE-conjugated a4-integrin antibody and FITC-conjugated b1-integrin antibody. Colocalization of the two subunits on cell membrane was confirmed by merging the images. At 48 h after transient transfection, cells were trypsinized and sorted by magnetic cell separator (IMAC) in sterile condition based on a4-integrin positivity. The a4-integrin-positive cell population was used in transplantation experiments in vivo.
Transplantation of marked MSC into syngeneic female mice and analysis of donor cell engraftment
The recipient animals, 6-week-old ovariectomized female C57BL/6 mice, were grouped in 10 mice each. Mocktransduced or rAAV2 (GFP or Col1-BMP2)-transduced MSC were resuspended in a volume of 100 ml saline and i.v. administered into recipient mice through tail vein. Before in vivo administration, the cells were transiently 28 Quantification of BMP2 level in the serum samples of transplanted animals BMP2 level in the mouse serum collected from the animals at different time points was determined by BMP2 Quantikine kit (R&D Systems). A standard curve was generated using purified rhBMP2 protein.
DXA and micro-CT analyses of bone
For DXA analysis, animals were briefly anesthetized with isoflurane (2%) and placed in a prostrate position on the imaging plate. BMD, BMC and other body composition were assessed in vivo by DXA (PIXImus software, version 1.45; GE-Lunar, Madison, WI, USA) periodically. To assess bone density, bone mass, geometry and bone microarchitecture, we scanned intact right femur from each mouse using high-resolution micro-CT imaging system (mCT40; Scanco Medical, Bassersdorf, Switzerland). Histomorphometric parameters including bone volume, trabecular connectivity, trabecular thickness, trabecular separation and DA were evaluated.
Histology and immunohistochemistry
Formalin-fixed tissues were decalcified in EDTA solution for 2 weeks and were embedded in paraffin. Longitudinal sections of 5 mm thicknesses were cut from paraffin-embedded blocks of frontal sections of tibia, using a Leica 2265 microtome (Leica, Wetzlar, Germany). For immunohistochemistry, 5 mm sections from each block were mounted onto treated slides. Following rehydration, antigen retrieval was performed in a highsteam cooker for 10 min; then slides were treated with 3% H 2 O 2 for 5 min to quench the endogenous peroxidase activity, blocked with preimmune goat serum (1%) for 20 min and incubated with anti-GFP antibody for 1 h. A delete was included in each staining procedure for each slide by omitting the primary antibody from the staining procedure. All slides were than incubated with secondary antibody conjugated to HRP for 30 min. Finally, slides were developed with the substrate 3,3 0 -diaminobenzidine for visualization of antigen-antibody complex and counterstained lightly with hematoxylin.
Quantitation of repopulated donor MSC in different tissues
Quantitation of donor cells that homed to different organs was determined by real-time PCR using genomic DNA isolated from tissues from recipient mice. Total DNA was isolated from different tissues. Quantitative real-time PCR was performed using GFP-specific primers in a Bio-Rad iCycler (optical module) using SYBR Green I dye kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's instructions. PCR products were subjected to melting curve analysis using the light cycler system to exclude amplification of nonspecific sequences. Values obtained from amplification of vectorspecific sequences from each sample were normalized to copy number of GAPDH gene amplification from the same sample to derive the relative vector copy number.
Determination of endogenous osteoblast progenitor cell mobilization
To distinguish transplanted MSC from endogenous MSC in target tissues and to determine whether transplanted MSC increase bone density directly or indirectly, we derived donor cells from transgenic, GFP-positive mice and transplanted them into ovariectomized syngeneic female recipients. A total of 2 Â 10 6 MSC were administered per mouse for 5 consecutive days of i.v. injection. Cohorts of mice were killed at weeks 1, 5 and 15 following MSC transplantation and long bones were fixed in 10% buffered formalin, followed by decalcification and mounting. Sections (5 mm) were prepared and stained with Runx2 and GFP antibodies to localize donor MSC in different areas of the bone. The slides were also stained by trichrome method to determine the location of GFP-positive donor MSC. The number of Runx2-positive cells in each area was quantified microscopically.
Cell proliferation assay of MSC isolated from transplanted animals
Bone marrow from the animals after 5 weeks, which were previously transplanted with MSC, was flushed from the long bones and cultured for a week. MSC cells were seeded in 96-well plates (Falcon 3072; Becton Dickinson, Lincoln Park, NJ, USA) at a density of 5000 cells per well and incubated at 37 1C in MSC medium supplemented with 10% FBS (MSC expansion medium catalog no. 1569-1L; Sigma) for 4 days, cell growth was measured by using a nonradioactive cell proliferation assay kit (CellTiter 96 Aqueous from Promega). On days 2, 4, 6 and 8 optical density was determined at 490 nm in a multiwell plate reader (BioTek Synergy 2; Winooski, Vermont, USA). Background absorbance of the medium in the absence of cells was subtracted. All samples were assayed in triplicate, and the mean for each experiment was calculated.
Flow cytometry
To determine the phenotypic characteristics of MSC isolated and cultured from the experimental animals, we trypsinized and washed MSC twice with FACS buffer (phosphate-buffered saline containing 2% FBS, 0.1% sodium azide). MSC were stained with PE-labeled CD29 (eBiosciences) and FITC-labeled Runx2 antibodies (R&D Systems) and analyzed by FACS Aria flow cytometer (BD Biosciences).
Statistical analysis
All data are reported as mean ± standard deviation (s.d.). Comparison of differences between two variables was performed using the two-tailed, two-sample with equal variances, independent t-test. BMD, BMC, lean tissue mass and fat tissue mass were analyzed using ANOVA. Nonparametric data were analyzed using Tukey's studentized range (honestly significant difference) and Kruskal-Wallis tests. Results were considered significant when Po0.05. 
